Myriad Genetics Q3 Profit Tops View; Lifts FY14 Outlook - Quick Facts

(RTTNews) - Myriad Genetics Inc. (MYGN), a molecular diagnostic company, Tuesday reported third-quarter net income of $36.8 million or $0.48 per share compared with $37.9 million or $0.46 per share last year.

Revenues for the quarter were $182.92 million, up 17% from $156.47 million in the prior year.

Analysts polled by Thomson Reuters estimated earnings of $0.45 per share on revenues of $175.23 million for the quarter. Analysts' estimates typically exclude special items.

The company lifted its outlook for fiscal year 2014 and now expects earnings of $2.37 to $2.40 per share on revenues of $770 million to $775 million. It earlier estimated earnings of $2.09 to $2.12 per share on revenues of $740 million to $750 million.

Analysts currently expect earnings of $2.19 per share on revenues of $764.01 million for the year.